Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001649553-25-000010
Filing Date
2025-01-23
Accepted
2025-01-23 12:19:49
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 9408
2 LIMITED POWER OF ATTORNEY slxn-sc13_exi.pdf EX-1 70124
3 JOINT FILING AGREEMENT slxn-sc13g_exii.pdf EX-2 64642
  Complete submission text file 0001649553-25-000010.txt   197179
Mailing Address P.O. BOX 309 UGLAND HOUSE GRAND CAYMAN E9 KY1-1104
Business Address P.O. BOX 309 UGLAND HOUSE GRAND CAYMAN E9 KY1-1104 345-949-8080
CVI Investments, Inc. (Filed by) CIK: 0001649553 (see all company filings)

EIN.: 981253664 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13G

Mailing Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606
Business Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606 972-8-6286005
Silexion Therapeutics Corp (Subject) CIK: 0002022416 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-94600 | Film No.: 25548902
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)